Shares of ImmuPharma plc (LON:IMM – Get Free Report) fell 3.9% on Tuesday . The stock traded as low as GBX 3.21 ($0.04) and last traded at GBX 3.60 ($0.04). 5,849,024 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 27,497,447 shares. The stock had previously closed at GBX 3.75 ($0.05).
ImmuPharma Trading Down 4.1 %
The stock has a market cap of £14.95 million, a P/E ratio of -359.00 and a beta of 1.53. The stock’s 50-day moving average is GBX 1.48 and its 200-day moving average is GBX 1.66.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Quiet Period Expirations Explained
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- What is Insider Trading? What You Can Learn from Insider Trading
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
